EP 3911415 A1 20211124 - DAPSONE FORMULATIONS AND METHODS OF USING SAME
Title (en)
DAPSONE FORMULATIONS AND METHODS OF USING SAME
Title (de)
DAPSON-FORMULIERUNGEN UND VERFAHREN ZU DEREN VERWENDUNG
Title (fr)
FORMULATIONS DE DAPSONE ET LEURS PROCÉDÉS D'UTILISATION
Publication
Application
Priority
- US 202063001972 P 20200330
- US 202063029685 P 20200525
- CA 3083002 A 20200610
- CA 2021050425 W 20210330
Abstract (en)
[origin: WO2021195765A1] A method for treating patients with COVID-19 and/or other respiratory conditions include administering a dosage of 75-100 milligrams of dapsone twice daily. A variety of dapsone formulation and delivery devices are disclosed, including an inhaler, nasal spray, nasal gel, otic formulation, intravenous formulation, oral solution, oral suspension, patch and suppository.
IPC 8 full level
A61P 31/14 (2006.01)
CPC (source: EP)
A61K 9/0043 (2013.01); A61K 9/0075 (2013.01); A61K 9/10 (2013.01); A61K 31/136 (2013.01); A61K 31/16 (2013.01); A61K 31/65 (2013.01); A61K 31/7052 (2013.01); A61K 47/10 (2013.01); A61P 31/14 (2017.12)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
WO 2021195765 A1 20211007; EP 3911415 A1 20211124; EP 3911415 A4 20221012
DOCDB simple family (application)
CA 2021050425 W 20210330; EP 21742678 A 20210330